Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $6.69 million. The enterprise value is $3.44 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 6.17 million shares outstanding. The number of shares has increased by 24.72% in one year.
| Current Share Class | 6.17M |
| Shares Outstanding | 6.17M |
| Shares Change (YoY) | +24.72% |
| Shares Change (QoQ) | -6.75% |
| Owned by Insiders (%) | 2.81% |
| Owned by Institutions (%) | 6.55% |
| Float | 4.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 1.04 |
| PS Ratio | 0.08 |
| Forward PS | 0.19 |
| PB Ratio | 0.22 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.61 |
| P/OCF Ratio | 9.95 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 1.41, with an EV/FCF ratio of 6.47.
| EV / Earnings | n/a |
| EV / Sales | 0.04 |
| EV / EBITDA | 1.41 |
| EV / EBIT | n/a |
| EV / FCF | 6.47 |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 0.56.
| Current Ratio | 0.98 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 3.86 |
| Debt / FCF | 32.28 |
| Interest Coverage | -1.15 |
Financial Efficiency
Return on equity (ROE) is -22.74% and return on invested capital (ROIC) is -6.26%.
| Return on Equity (ROE) | -22.74% |
| Return on Assets (ROA) | -2.51% |
| Return on Invested Capital (ROIC) | -6.26% |
| Return on Capital Employed (ROCE) | -9.51% |
| Revenue Per Employee | $757,176 |
| Profits Per Employee | -$51,392 |
| Employee Count | 102 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 2.22 |
Taxes
In the past 12 months, Aytu BioPharma has paid $1.11 million in taxes.
| Income Tax | 1.11M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.12% in the last 52 weeks. The beta is 0.07, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -62.12% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.85 |
| Relative Strength Index (RSI) | 46.96 |
| Average Volume (20 Days) | 31,900 |
Short Selling Information
The latest short interest is 118,651, so 1.92% of the outstanding shares have been sold short.
| Short Interest | 118,651 |
| Short Previous Month | 117,335 |
| Short % of Shares Out | 1.92% |
| Short % of Float | 2.64% |
| Short Ratio (days to cover) | 3.29 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $77.23 million and -$5.24 million in losses. Loss per share was -$1.90.
| Revenue | 77.23M |
| Gross Profit | 50.45M |
| Operating Income | -4.96M |
| Pretax Income | -12.61M |
| Net Income | -5.24M |
| EBITDA | 2.44M |
| EBIT | -4.96M |
| Loss Per Share | -$1.90 |
Full Income StatementBalance Sheet
The company has $20.40 million in cash and $17.14 million in debt, giving a net cash position of $3.26 million or $0.53 per share.
| Cash & Cash Equivalents | 20.40M |
| Total Debt | 17.14M |
| Net Cash | 3.26M |
| Net Cash Per Share | $0.53 |
| Equity (Book Value) | 30.77M |
| Book Value Per Share | 4.99 |
| Working Capital | -995,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $673,000 and capital expenditures -$142,000, giving a free cash flow of $531,000.
| Operating Cash Flow | 673,000 |
| Capital Expenditures | -142,000 |
| Free Cash Flow | 531,000 |
| FCF Per Share | $0.09 |
Full Cash Flow StatementMargins
Gross margin is 65.32%, with operating and profit margins of -6.42% and -6.79%.
| Gross Margin | 65.32% |
| Operating Margin | -6.42% |
| Pretax Margin | -7.93% |
| Profit Margin | -6.79% |
| EBITDA Margin | 3.16% |
| EBIT Margin | -6.42% |
| FCF Margin | 0.69% |